Literature DB >> 30241002

Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century.

Fabien Calvo1, Giovanni Apolone2, Michael Baumann3, Carlos Caldas4, Julio E Celis5, Franceso de Lorenzo6, Ingemar Ernberg7, Ulrik Ringborg7, John Rowell1, Josep Tabernero8, Emile Voest9, Alexander Eggermont10.   

Abstract

Translational cancer research covers the whole cancer research continuum from basic to preclinical to early clinical, late clinical and outcomes research. Basic-preclinical research is the "engine" for early clinical research bridging the early translational research gap. Cancer Core Europe has been created to construct a sustainable, high level, shared research infrastructure platform with research collaborations and taskforces (data sharing, clinical trials, genomics, immunotherapy, imaging, legal & ethical problems, and education & training) having representatives from all seven member centres, in a controlled expansion model. In parallel, a consortium of ten cancer prevention centres was established, Cancer Prevention Europe, to support the complete cancer prevention research continuum. Cancer Core Europe is launching at present the Basket of Baskets trial, which is the largest personalized cancer medicine trial effort in Europe. At present, Cancer Core Europe and Cancer Prevention Europe are in the process of integrating therapeutics and prevention strategies to address in partnership the increasing cancer problem. By offering innovative approaches for cancer research, links to the healthcare systems, development of quality-assured multidisciplinary cancer care, as well as the assessment of long-term outcomes, the infrastructure is expected to serve as a hub to connect with other centres in Europe as well as on other continents. In this manner Cancer Core Europe and Cancer Prevention Europe prepare to tackle the "Mission on Cancer", with infrastructure and proofs of concept for therapeutics and prevention, research for assessment of effectiveness, health economics and added value for patients and the healthcare systems.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Alliance; Cancer research; Infrastructure; Innovation; Oncopolicy

Mesh:

Year:  2018        PMID: 30241002     DOI: 10.1016/j.ejca.2018.08.023

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  Translational cancer research - a coherent cancer research continuum.

Authors:  Ulrik Ringborg
Journal:  Mol Oncol       Date:  2019-02-01       Impact factor: 6.603

Review 2.  Cancer Core Europe: A translational research infrastructure for a European mission on cancer.

Authors:  Alexander M M Eggermont; Giovanni Apolone; Michael Baumann; Carlos Caldas; Julio E Celis; Francesco de Lorenzo; Ingemar Ernberg; Ulrik Ringborg; John Rowell; Josep Tabernero; Emile Voest; Fabien Calvo
Journal:  Mol Oncol       Date:  2019-02-02       Impact factor: 6.603

3.  A report from a conference jointly organised by the European Academy of Cancer Sciences and the Pontifical Academy of Sciences, The Vatican, November 16-17, 2018.

Authors: 
Journal:  Mol Oncol       Date:  2019-02-27       Impact factor: 6.603

4.  Boosting the social impact of innovative cancer research - towards a mission-oriented approach to cancer.

Authors:  Ulrik Ringborg; Julio E Celis; Michael Baumann; Alexander Eggermont; Christopher P Wild; Anton Berns
Journal:  Mol Oncol       Date:  2019-02-27       Impact factor: 6.603

Review 5.  Quality-assured research environments for translational cancer research.

Authors:  Anton Berns
Journal:  Mol Oncol       Date:  2019-02-22       Impact factor: 6.603

Review 6.  New clinical trial designs in the era of precision medicine.

Authors:  Elena Garralda; Rodrigo Dienstmann; Alejandro Piris-Giménez; Irene Braña; Jordi Rodon; Josep Tabernero
Journal:  Mol Oncol       Date:  2019-02-22       Impact factor: 6.603

7.  Towards a cancer mission in Horizon Europe: recommendations.

Authors:  Anton Berns; Ulrik Ringborg; Julio E Celis; Manuel Heitor; Neil K Aaronson; Nancy Abou-Zeid; Hans-Olov Adami; Kathi Apostolidis; Michael Baumann; Alberto Bardelli; René Bernards; Yvonne Brandberg; Carlos Caldas; Fabien Calvo; Caroline Dive; Angelika Eggert; Alexander Eggermont; Carolina Espina; Frederik Falkenburg; Jérôme Foucaud; Douglas Hanahan; Ulrike Helbig; Bengt Jönsson; Mette Kalager; Sakari Karjalainen; Miklós Kásler; Pamela Kearns; Klas Kärre; Denis Lacombe; Francesco de Lorenzo; Françoise Meunier; Gerd Nettekoven; Simon Oberst; Péter Nagy; Thierry Philip; Richard Price; Joachim Schüz; Eric Solary; Peter Strang; Josep Tabernero; Emile Voest
Journal:  Mol Oncol       Date:  2020-08       Impact factor: 6.603

8.  Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials.

Authors:  Rodrigo Dienstmann; Elena Garralda; Susana Aguilar; Gemma Sala; Cristina Viaplana; Fiorella Ruiz-Pace; Jenifer González-Zorelle; Deborah Grazia LoGiacco; Zighereda Ogbah; Laia Ramos Masdeu; Francesco Mancuso; Roberta Fasani; Jose Jimenez; Paola Martinez; Ana Oaknin; Cristina Saura; Mafalda Oliveira; Judith Balmaña; Joan Carles; Teresa Macarulla; Elena Elez; Maria Alsina; Irene Braña; Enriqueta Felip; Josep Tabernero; Jordi Rodon; Paolo Nuciforo; Ana Vivancos
Journal:  JCO Precis Oncol       Date:  2020-05-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.